Irm LLC

Novartis Ag

Other

Hamilton

Juliet Nabakka

Valentina Molteni

Xiaolin Li

Jon Christopher Loren

Xiaodong Liu

Donatella Chianelli

Shuli You

Vince S Yeh

Yi Liu

Pascal Furet

Donald Karanewsky

Bao Vinh Nguyen

Vito Guagnano

Shifeng Pan

Hank Michael James Petrassi

John Wityak

Yun He

Enrique Saez

Xiaohui He

Zuosheng Liu

Kunyong Yang

Beth Anaclerio

Andreas Kreusch

Pingda Ren

Xiaodong Wang

Werner Breitenstein

Songchun Jiang

Fang Liang

Taebo Sim

David Archer Ellis

Timothy M Ramsey

Christopher Cow

Xiadong Liu

Valentina Molenti

Hank Michael Petrassi

Donald S Karanewsky

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR&#x3b1;, PDGFR&#x3b2;) kinases.

Compounds and compositions as C-kit kinase inhibitors

Compounds and compositions as c-kit kinase inhibitors

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

Compounds and compositions as LXR modulators

Compounds and compositions as c-Kit kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.

Compounds and compositions as c-kit and PDGFR kinase inhibitors

The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1;, PDGFR&#x3b2;, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2&#x3b2;, BRK, Fms, KDR, c-rapor b-raf kinases. 

5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors

The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1;, PDGFR&#x3b2;, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2&#x3b2;, BRK, Fms, KDR, c-raf or b-raf kinases. 

2-heteroarylamino-pyrimidine derivatives as kinase inhibitors

The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1; and PDGFR&#x3b2; kinases. 

Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors

The invention provides compounds of Formula (2), and pharmaceutical compositions thereof, wherein R, R, R, Rand L are as described herein; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1;, PDGFR&#x3b2;, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2&#x3b2;, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Compositions and methods for modulating c-kit and PDGFR receptors

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1;, PDGFR&#x3b2;, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2&#x3b2;, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors

Growing community of inventors

San Diego, CA, United States of America

Juliet Nabakka